Risk of Active Tuberculosis During Anti-TNF-α Inhibitor Use to Treat Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials

被引：0
作者：
Wu, Hanxin [1 ]
Peng, Li [1 ]
Ma, Weijie [1 ]
Zhu, Liangyu [1 ]
Wu, Xinya [1 ]
Gao, Li [1 ]
Zhong, Lei [1 ]
Song, Jieqin [1 ]
Li, Bingxue [1 ]
Huang, Xun [1 ]
Yang, Rui [1 ]
Bao, Fukai [1 ,2 ]
Liu, Aihua [1 ,2 ]
机构：
[1] Kunming Med Univ, Inst Trop Med, Fac Basic Med Sci, Evidence Based Med Team, Kunming 650500, Yunnan, Peoples R China
[2] Kunming Med Univ, Affiliated Childrens Hosp, Yunnan Prov Key Lab Childrens Major Dis Res, Kunming 650030, Yunnan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF BIOMEDICINE | 2024年 / 14卷 / 03期
基金：
中国国家自然科学基金;
关键词：
rheumatoid arthritis; tuberculosis; TNF-alpha inhibitor; meta-analysis; ADALIMUMAB PLUS METHOTREXATE; PLACEBO-CONTROLLED TRIAL; LONG-TERM EXTENSION; DOUBLE-BLIND; PHASE-III; EULAR RECOMMENDATIONS; INADEQUATE RESPONSE; CERTOLIZUMAB PEGOL; CLINICAL-TRIAL; INFLIXIMAB;
D O I：
10.21103/Article14(3)_RA1
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background: Given the wide application of TNF-alpha inhibitors for the treatment of rheumatoid arthritis (RA), more active tuberculosis cases have been reported in patients with RA. This meta-analysis was performed to evaluate the risk of active tuberculosis (TB) in RA patients undergoing treatment with TNF-alpha inhibitors. Methods and Results: Thirty randomized controlled trials (RCTs), comprising 18,640 patients, were included in the meta-analysis after searching PubMed, EMBASE, and Web of Science databases. Overall, there was a higher risk of active TB in patients with RA undergoing treatment with TNF-alpha inhibitors than in the control group (Peto OR, 2.57; 95%CI, 1.42-4.66; P=0.002). Conclusion: Our meta-analysis showed that RA patients treated with TNF-alpha inhibitors had a higher risk of developing active TB. Tuberculosis screening should be performed before and during the use of TNF-alpha inhibitors in these patients.
引用
收藏
页码：371 / 378
页数：182
相关论文
共 58 条
  • [1] Abe T, 2006, J RHEUMATOL, V33, P37
  • [2] Bi L, 2019, CLIN EXP RHEUMATOL, V37, P227
  • [3] Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial
    Bingham, Clifton O., III
    Mendelsohn, Alan M.
    Kim, Lilianne
    Xu, Zhenhua
    Leu, Jocelyn
    Han, Chenglong
    Lo, Kim Hung
    Westhovens, Rene
    Weinblatt, Michael E.
    [J]. ARTHRITIS CARE & RESEARCH, 2015, 67 (12) : 1627 - 1636
  • [4] Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritis
    Braun, Tobias
    Zwerina, Jochen
    [J]. ARTHRITIS RESEARCH & THERAPY, 2011, 13 (04)
  • [5] The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
    Breedveld, FC
    Weisman, MH
    Kavanaugh, AF
    Cohen, SB
    Pavelka, K
    van Vollenhoven, R
    Sharp, J
    Perez, JL
    Spencer-Green, GT
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (01): : 26 - 37
  • [6] Long-term outcome of Rheumatoid Arthritis defined according to the 2010-classification criteria
    Burgers, L. E.
    van Nies, J. A. B.
    Ho, L. Y.
    de Rooy, D. P. C.
    Huizinga, T. W. J.
    van der Helm-van Mil, A. H. M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (02) : 428 - 432
  • [7] Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
    Clair, EWS
    van der Heijde, DMFM
    Smolen, JS
    Maini, RN
    Bathon, JM
    Emery, P
    Keystone, E
    Schiff, M
    Kalden, JR
    Wang, B
    DeWoody, K
    Weiss, R
    Baker, D
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (11): : 3432 - 3443
  • [8] Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death
    Clay, Hilary
    Volkman, Hannah E.
    Ramakrishnan, Lalita
    [J]. IMMUNITY, 2008, 29 (02) : 283 - 294
  • [9] de Souza S, 2023, Ann Rheum Dis, V82, P107, DOI [10.1136/ard-2022-223357, DOI 10.1136/ARD-2022-223357]
  • [10] Lifestyle, Hormonal, and Metabolic Environmental Risks for Rheumatoid Arthritis
    Desai, Nancy
    Federico, Lydia
    Baker, Joshua F.
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2022, 48 (04) : 799 - 811
123456